Irritable Bowel Syndrome

Videlock, Elizabeth J.; Chang, Lin

doi:10.1002/9781118512074.ch75

Cited by 2 publications

(1 citation statement)

References 473 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Irritable bowel syndrome (IBS) is now recognized to be common worldwide and to be most common among adolescent and young adult females [ 1 , 2 , 3 ]. The clinical and socioeconomic impact of IBS varies—for some it is a nuisance, for others it disrupts every aspect of their daily lives—work, school, personal and social relationships [ 4 ]. IBS is not a new disorder; what is new is its acceptance as a “real” and potentially incapacitating disorder by the health care profession and the general public alike.…”

Section: Ibs—an Introductionmentioning

confidence: 99%

The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS)

Quigley

2018

JCM

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is one of the most common of all medical disorders worldwide and, while for some it represents no more than a nuisance, for others it imposes significant negative impacts on daily life and activities. IBS is a heterogeneous disorder and may well have a number of causes which may lie anywhere from the external environment to the contents of the gut lumen and from the enteric neuromuscular apparatus and the gut immune system to the central nervous system. Consequently, the paradigm of the gut-brain axis, which includes the participation of these various factors, has proven a useful model to assist clinicians and patients alike in understanding the genesis of symptoms in IBS. Now, given the widespread interest in the gut microbiome in health and disease, in general, reports of disordered enteric bacterial communities in IBS, and experimental data to indicate that components of the gut microbiota can influence brain morphology and function, as well as behavior and cognition, this concept has been extended to encompass the microbiota-gut-brain axis. The implications of this novel concept to the assessment and management of IBS will be explored in this review.

show abstract

Section: Ibs—an Introductionmentioning

confidence: 99%

The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS)

Quigley

2018

JCM

View full text Add to dashboard Cite

show abstract

Unique strain of Bifidobacterium longum and its efficacy in irritable bowel syndrome

Плотникова

2021

Medicinskij sovet

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is one of the most prevalent gastrointestinal disorders affecting between 5 and 15% of the general adult population worldwide. Over the course of many years altered intestinal motility, visceral hypersensitivity, immune changes and, as it has recently been found, impaired epithelial barrier function were meant to explain the origin of symptoms in the IBS. We have come to realize now that the IBS warrants serious clinical and scientific study. Not that long ago, the connections between the gut and the brain have been expanded to include a new entrant, the microbiota, resulting in the creation of a new concept of a microbiota-gut-brain axis.Microbiota is a risk factor for the irritable bowel syndrome. Probiotics are defined as live microorganisms, which can alter the intestinal flora and regulate intestinal functions such as reduction of visceral hypersensitivity, improvement of mucosal barrier function, modulate immune responses and chronic inflammation, affect the central nervous system, gastrointestinal motility, etc. The correctness of this approach is confirmed by several studies of the probiotic Bifidobacterium longum subsp. longum 35624, which is widely used in the treatment of symptoms of irritable bowel syndrome. The dietary supplement Bifidobacterium longum subsp. longum 35624 contains 1 × 109 colony-forming units, which provides a clinically effective level of these beneficial bacteria. Bifidobacterium longum subsp. longum 35624 also reduces inflammation in the gastrointestinal tract and has positive results in reducing abdominal symptoms (e.g. abdominal pain / discomfort and bloating) associated with the irritable bowel syndrome and other conditions.

show abstract

Irritable Bowel Syndrome

Cited by 2 publications

References 473 publications

The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS)

The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS)

Unique strain of Bifidobacterium longum and its efficacy in irritable bowel syndrome

Contact Info

Product

Resources

About